Chairman of Shaanxi Branch of China Rheumatology Society;
Executive Director of Shaanxi Branch of China Immunology Society;
Member of Clinical Immunology Branch of Chinese Immunology Society;
Vice Chairman of Clinical Immunity of Xi Branch of Chinese Medical Association;
Vice Chairman of Xi Branch of Rheumatology of Chinese Medical Association;
Editorial Committee of Chinese Journal of Rheumatology.
Professional knowledge:
Rheumatology, clinical immunology.
Engaged in medical and teaching work for a long time. Engaged in scientific research.
This paper mainly studies the disease mechanism mediated by rabbit epidemic and the application of new technology in the diagnosis and treatment of directional diseases.
He has successively undertaken four national-level projects, including the National Natural Science Foundation, the National Science and Technology Key Program, the National High-tech Research and Development Program 863 and the "10.5" project, and served as the project leader.
In recent years, he has published many papers in major journals at home and abroad, won 2 national invention patents, won the first prize of national scientific and technological progress and won the first and second prizes of military scientific and technological progress.
Professor Zhu Ping has been a doctor for 33 years and has accumulated rich experience in treating patients with difficult and severe rheumatoid immune diseases. He has been engaged in the research on immune-mediated mechanism and new technologies for diagnosis and treatment of rheumatoid immune diseases such as rheumatoid arthritis for a long time, and has created more than 10 new technologies and services, of which 4 are at the leading level in China: (1) Clinical and clinical basic research on new technologies and new preparations for immunotherapy; (2) Comprehensive medical and surgical diagnosis and treatment techniques for inflammatory arthropathy; (3) Screening early warning indicators of organ injury to guide early diagnosis and treatment; (4) Research and establish the diagnosis and evaluation system of health and disease immunity. Lead or participate in 28 multi-center clinical studies. The functional research system of CD 147 molecule mediating the injury and anti-injury of rheumatoid arthritis was established, and the binding sites of CD 147 and its ligands were obtained, which laid an important foundation for the research of new anti-inflammatory drugs.
He has successively undertaken two key projects of the National Natural Science Foundation, national "863" plan, national "973" plan project leader, major new drug creation and other national projects; 4 national invention patents, 2 international patents (Germany and the United States) and 3 national invention patents; Published 34 SCI papers, including 29 first authors or correspondent authors, with the impact factor of146.837; Chief editor of four monographs; Won 2 second prizes for national scientific and technological progress, 3 first prizes for provincial and ministerial science and technology, and the second prize 1 item.